Global Molecular Biology Enzymes & Kits & Reagents Market Insights, Size and Growth Forecast To 2030

Molecular Biology Enzymes & Kits & Reagents Market Size, Share & Trends Analysis By Product, By Application, By End User, Regional Outlook, Competitive Strategies and Segment Forecasts to 2030

Published: Jun-2022	Report ID: BIOT2232	Pages: 1 - 256	Formats^*:
Category : Biotechnology

Global Molecular Biology Enzymes & Kits & Reagents Market Overview:

According to SPER Market Research, the Molecular Biology Enzymes & Kits & Reagents Market estimated to reach USD 48.21 billion by 2030 with a CAGR of 13.6%. Amplified research, investments, increasing number of genome projects, technological advancement in the life science industry, and growing incidence of genetic disorders; are the fuels for the escalation of the market.

Impact of COVID-19 on the Molecular Biology Enzymes & Kits & Reagents Market

The outbreak of COVID-19 gives a positive impact to the expansion Molecular Biology Enzymes & Kits & Reagents Market.

Scope of the report:

Report Metric	Details
Market size available for years	2019-2030
Base year considered	2021
Forecast period	2022-2030
Segments covered	By Material, By Technique, By Application, By End-Users, By Region
Geographies covered	North America, Europe, Asia Pacific, Latin America, Middle East, Africa
Companies Covered	ADS Biotec Inc., Agilent, Aldevron, Bio Basic, Bio-Rad Laboratories, Inc.Â¸Genekam Biotechnology, Goldsite Diagnostics Inc., Hangzhou Matridx Biotechnology Co. Ltd., Illumina, Integrated DNA Technologies, Inc., Jena Bioscience, LGC Biosearch Technologies, Lucigen Corporation, Merck, MoBiTec GmbH, Molecular Biology Resources, New England Biolabs, NZYTech, Promega, QIAGEN, Randox, Roche, Takara Bio, Thermo Fisher, Zymo Research Corporation

Driver: increasing number of genome projects

The increasing numeral of genome projects globally, tied with dipping genetic analysis costs; leads to advancement in research in diverse fields like; personalized medicine, microbial genetic, disease treatment. This research need the use of molecular biology enzymes and reagents, consequently impel the expansion of this molecular biology enzymes and kits & reagents market.

Restraints: restricted reimbursements for genetic testing

The inflexible reimbursement policy is the restraints to this market.

Opportunity: Research & Development investments offer significant opportunities for the market

Increase in the funds & grants from the government, advancement in the genomic technological facade, investments in research & development have vast opportunities for this market.

Molecular Biology Enzymes & Kits & Reagents Market Segmentation:

By Product: Based on the Product, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; Kits & Reagents, Enzymes, Polymerases, Ligases, Restriction Endonucleases, Reverse Transcriptases, Other Enzymes.

By Application: Based on the Application, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; PCR, Sequencing, Cloning, Epigenetics, Restriction Digestion, Synthetic Biology, Other Applications.

By End User: Based on the End-Users, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; Academic & Research Institutes, Pharmaceutical & Biotechnology companies, Hospitals & Diagnostic Centers, Other End Users.

By Region: North America dominates the biggest share of this market; this is due to the increase in funding of translational and clinical research, increasing the figure of pharmaceutical and biotechnology companies, rising investments in research projects in Canada favourable reimbursement scenario.

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1 Research data source

2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPERâ€™s internal database
2.1.4 Premium insight from KOLâ€™s

2.2 Market size estimation

2.2.1 Top-down and Bottom-up approach

2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis

4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges

4.2. COVID-19 Impacts of the Molecular Biology Enzymes & Kits & Reagents Market

5. Market variables and outlook

5.1. SWOT analysis

5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats

5.2. PESTEL analysis

5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape

5.3. PORTERâ€™S five forces analysis

5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry

5.4. Heat map analysis

6. Molecular Biology Enzymes & Kits & Reagents Market, By Product, 2019-2030 (USD Million)

6.1. Kits & Reagents
6.2. Enzymes
6.3. Polymerases
6.4. Ligases
6.5. Restriction Endonucleases
6.6. Reverse Transcriptases
6.7. Other Enzymes

7. Molecular Biology Enzymes & Kits & Reagents Market, By Application, 2019-2030 (USD Million)

7.1. PCR
7.2. Sequencing
7.3. Cloning
7.4. Epigenetics
7.5. Restriction Digestion
7.6. Synthetic Biology
7.7. Other Applications

8. Molecular Biology Enzymes & Kits & Reagents Market, By End User, 2019-2030 (USD Million)

8.1. Academic & Research Institutes
8.2. Pharmaceutical & Biotechnology companies
8.3. Hospitals & Diagnostic Centers
8.4. Other End Users

9. Molecular Biology Enzymes & Kits & Reagents Market, By Region, 2019-2030 (USD Million)

9.1. North America

9.1.1. United States
9.1.2. Canada
9.1.3. Mexico

9.2. Europe

9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe

9.3. Asia-Pacific

9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific

9.4. South America

9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America

9.5. Middle East & Africa

9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa

10. Company Profiles

10.1. ADS Biotec Inc.

10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments

10.2. Agilent

10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments

10.3. Aldevron

10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments

10.4. Bio Basic

10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments

10.5. Bio-Rad Laboratories Inc.

10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments

10.6. Genekam Biotechnology

10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments

10.7. Goldsite Diagnostics Inc.

10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments

10.8. Hangzhou Matridx Biotechnology Co. Ltd.

10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments

10.9. Illumina

10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments

10.10. Integrated DNA Technologies, Inc.

10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments

10.11. Jena Bioscience

10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments

10.12. LGC Biosearch Technologies

10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments

10.13. Lucigen Corporation

10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments

10.14. Merck

10.14.1. Company details
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments

10.15. MoBiTec GmbH

10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments

10.16. Molecular Biology Resources

10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent developments

10.17. New England Biolabs

10.17.1. Company details
10.17.2. Financial outlook
10.17.3. Product summary
10.17.4. Recent developments

10.18. NZYTech

10.18.1. Company details
10.18.2. Financial outlook
10.18.3. Product summary
10.18.4. Recent developments

10.19. Promega

10.19.1. Company details
10.19.2. Financial outlook
10.19.3. Product summary
10.19.4. Recent developments

10.20. QIAGEN

10.20.1. Company details
10.20.2. Financial outlook
10.20.3. Product summary
10.20.4. Recent developments

10.21. Randox

10.21.1. Company details
10.21.2. Financial outlook
10.21.3. Product summary
10.21.4. Recent developments

10.22. Roche

10.22.1. Company details
10.22.2. Financial outlook
10.22.3. Product summary
10.22.4. Recent developments

10.23. Takara Bio

10.23.1. Company details
10.23.2. Financial outlook
10.23.3. Product summary
10.23.4. Recent developments

10.24. Thermo Fisher

10.24.1. Company details
10.24.2. Financial outlook
10.24.3. Product summary
10.24.4. Recent developments

10.25. Zymo Research Corporation

10.25.1. Company details
10.25.2. Financial outlook
10.25.3. Product summary
10.25.4. Recent developments

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1